Nuveen Asset Management LLC Purchases 425,484 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Nuveen Asset Management LLC raised its position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 42.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,432,404 shares of the biotechnology company's stock after purchasing an additional 425,484 shares during the period. Nuveen Asset Management LLC owned approximately 0.21% of OPKO Health worth $2,106,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Barclays PLC increased its position in OPKO Health by 68.7% during the 4th quarter. Barclays PLC now owns 916,368 shares of the biotechnology company's stock worth $1,347,000 after purchasing an additional 373,032 shares in the last quarter. Norges Bank acquired a new position in shares of OPKO Health during the fourth quarter worth $1,657,000. Millennium Management LLC increased its holdings in shares of OPKO Health by 85.3% during the fourth quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company's stock worth $6,745,000 after buying an additional 2,112,382 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of OPKO Health by 4.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 455,521 shares of the biotechnology company's stock valued at $670,000 after acquiring an additional 18,571 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of OPKO Health by 14.9% during the 4th quarter. Wells Fargo & Company MN now owns 229,262 shares of the biotechnology company's stock valued at $337,000 after acquiring an additional 29,738 shares in the last quarter. 64.63% of the stock is currently owned by institutional investors.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 150,000 shares of the company's stock in a transaction that occurred on Friday, March 28th. The shares were acquired at an average price of $1.70 per share, with a total value of $255,000.00. Following the transaction, the chief executive officer now owns 213,651,448 shares in the company, valued at $363,207,461.60. The trade was a 0.07% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders purchased 700,000 shares of company stock valued at $1,123,000. Corporate insiders own 49.69% of the company's stock.

OPKO Health Trading Up 2.2%

Shares of OPK traded up $0.03 during mid-day trading on Thursday, reaching $1.38. 1,360,041 shares of the company were exchanged, compared to its average volume of 4,214,876. The business has a 50 day simple moving average of $1.39 and a two-hundred day simple moving average of $1.54. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The stock has a market capitalization of $1.09 billion, a PE ratio of -7.24 and a beta of 1.42. OPKO Health, Inc. has a 52 week low of $1.19 and a 52 week high of $2.04.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm had revenue of $149.90 million for the quarter, compared to the consensus estimate of $163.13 million. During the same quarter in the previous year, the business posted ($0.12) EPS. The firm's revenue for the quarter was down 13.7% compared to the same quarter last year. On average, analysts predict that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on OPK shares. Barrington Research reiterated an "outperform" rating and issued a $2.25 target price on shares of OPKO Health in a research report on Thursday, May 1st. HC Wainwright reiterated a "buy" rating and issued a $3.00 price objective on shares of OPKO Health in a report on Monday, April 7th. JPMorgan Chase & Co. assumed coverage on shares of OPKO Health in a research report on Friday, April 25th. They set a "neutral" rating on the stock. Finally, Wall Street Zen lowered shares of OPKO Health from a "hold" rating to a "sell" rating in a report on Monday, May 5th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $2.75.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.